Stephen Haworth
Direttore Tecnico/Scientifico/R&S presso XORTX THERAPEUTICS INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Stephen Haworth is currently the Chief Medical Officer at XORTX Therapeutics, Inc. He previously worked as the Executive Director-Medical at CorMedix, Inc. from 2017 to 2018, and as the Chief Medical Officer & Vice President at Elusys Therapeutics, Inc. from 2012 to 2013.
He also served as the Vice President at VaxInnate Corp.
from 2015 to 2016.
Haworth received his undergraduate degree from University College London and his doctorate from UCL Medical School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
XORTX THERAPEUTICS, INC.
-.--% | 04/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Stephen Haworth
| Società | Posizione | Inizio |
|---|---|---|
| XORTX THERAPEUTICS INC. | Direttore Tecnico/Scientifico/R&S | 01/07/2021 |
Precedenti posizioni note di Stephen Haworth
| Società | Posizione | Fine |
|---|---|---|
| CORMEDIX INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2018 |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Direttore Tecnico/Scientifico/R&S | 01/04/2013 |
VaxInnate Corp.
 VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | 01/04/2016 |
Formazione di Stephen Haworth
| UCL Medical School | Doctorate Degree |
| University College London | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| XORTX THERAPEUTICS INC. | Health Technology |
| CORMEDIX INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Health Technology |
VaxInnate Corp.
VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Health Technology |
- Borsa valori
- Insiders
- Stephen Haworth
